| IMAB - I-MAB ADR (Healthcare: Biotechnology) | Projected Earnings Date: 2024-07-01 (Delayed quote data 2025-01-03) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company's drug candidates are TJ202 for Multiple myeloma/Autoimmune diseases, TJ101 for Pediatric growth hormone deficiency, TJ301 for Ulcerative colitis/Autoimmune disease, Enoblituzumab for Head & neck cancer/Oncology, and TJ107 for Oncology-related lymphopenia. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |